Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis

Phase 3CompletedNCT00524836

UCB Pharma71 enrolled

Overview

Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Rhinitis Allergic Perennial

Interventions

levocetirizine dihydrochlorideDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male ore female, 16 to 60 years old (inclusive) * two-year history of allergic rhinitis due to house dust mite Exclusion Criteria: * An ear, nose or throat (ENT) infection * asthma requiring daily drug therapy other than ß2 inhaled agonists taken prn * atopic dermatitis or urticaria requiring an antihistamine or corticosteroid treatment * an associated ENT disease * use of decongestants * nasal or ocular topical treatment * desensitivation

Outcomes

Primary Outcomes

Total 5 Symptom Score (T5SS) rated by the investigator

Time frame: 2 weeks

Secondary Outcomes

Investigators global efficacy evaluation at the end of treatment; subject's rating of T5SS and individual symptoms (over the last 24 hours) over first week and the total 2 weeks treatment period; the Symptoms Score Reducing Index (SSRI).

Time frame: 2 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.